| ²é¿´: 330 | »Ø¸´: 0 | |||
summersherryÎÞ³æ (СÓÐÃûÆø)
|
[½»Á÷]
´Ó¼ÆËã»úÄ£Äâ/ÌåÍâµ½ÁÙ´²Ñо¿SeminarÔÚ¸´µ©Ò©Ñ§Ôº³É¹¦¾Ù°ì
|
|
ÎªÍØÕ¹Ò©Ñ§ÔºÑ§ÉúÐÂÒ©Ñз¢Ë¼Î¬£¬ÓªÔìÁ¼ºÃµÄ²úѧÑкÏ×÷·ÕΧ£¬Ìá¸ß¹ã´óʦÉúµÄ¿ÆÑÐˮƽ¡£¸´µ©Ò©Ñ§ÔºÔº³¤ÖìÒÀ×»ÌØÑû¸´µ©´óѧºú׿ºº½ÌÊÚ£¬ÃÀ¹úSimulations Plus¸±×ܲÃJohn DiBella£¬GSK DMPK×ܼàLiangfu Chen ÓÚ2013Äê10ÔÂ21ÈÕÔÚÕÅ½Ð£Çø½øÐÐÁ˾«²ÊÊڿΡ£ À´×ÔÕŽ¸÷ÖÆÒ©ÆóÒµÓ븴µ©Ý·Ý·Ñ§×Ó¹²¾ÛÒ»Ìã¬Ò»Í¬Ñ§Ï°ºÍ½»Á÷ÁË´Ó¼ÆËã»úÄ£Äâ/ÌåÍâµ½ÁÙ´²Ñо¿µÄ½²×ù¡£ÊÚ¿ÎÀÏÊ¦ÖØµã½²ÊöÁËFDA,CFDA¹ØÓÚDDI(Ò©ÎïÏ໥×÷ÓÃ)µÄÖ¸µ¼ÔÔò£¬DDIÔÀí£»ÒÔ¼°Ä¿Ç°¹ú¼ÊÍÆ¼öʹÓõÄModeling & Simulation·½·¨£¬Ò²½²½âÁËÖÆÒ©ÆóÒµ¹ØÓÚÒ©ÎïÏ໥×÷ÓõÄÑз¢²ßÂÔ¡£ ±¾´Î½²×ù·ÖΪÒÔÏÂÈý´óÖ÷Ì⣬ÓÉÈýλÀÏʦ·Ö±ð×÷³ö¾«²ÊµÄÑݽ²; 1¡¢In Vitro Studies ÌåÍâÑо¿ 2¡¢Silicon simulation/prediction ¼ÆËã»úÄ£Äâ¼°Ô¤²â 3¡¢Current practices in drug interaction risk assessment for enabling Clinical development ÁÙ´²Ñо¿ Ñݽ²ÀÏʦ£º 1¡¢Zhuohan Hu Professor of Fudan University CSO, Research Institute for Liver Diseases À´×ÔÈðµÂ¸ÎÔà/¸´µ©´óѧµÄºú½ÌÊÚ½éÉÜÁË¡¶In Vitro StudiesÌåÍâÑо¿¡· 2¡¢John DiBella Senior VP of Simulation Plus Inc. (USA) À´×ÔÃÀ¹úSimulations Plus ¹«Ë¾¸±×ܲõÄJohn Dibella×÷µÄ±¨¸æÌâĿΪ¡¶Silicon simulation/prediction ¼ÆËã»úÄ£Äâ¼°Ô¤²â¡· 3¡¢Liangfu Chen DMPK Director , GSK R&D Center in Shanghai. À´×ÔGSKµÄDMPK×ܼàLiangu Chen×÷µÄ±¨¸æÌâĿΪ¡¶Current practices in drug interaction risk assessment for enabling Clinical development ¡· Õû¸ö½²×ùÖУ¬ÈýλÊÚ¿ÎÀÏʦͨ¹ý¾ÙÀý¶Ô¸÷¸öϸ½Ú½øÐÐÁ˾«²Ê¡¢Ï꾡µÄ²ûÊö£¬Èôó¼Ò¶ÔÐÂÒ©Ñз¢ÓÐÁ˸ü¼ÓÖ±¹ÛµÄÈÏʶ¡£ÔÚÎÊ´ð»·½Ú£¬Ì¨ÏÂʦÉú¸üÊÇÓ»Ô¾»¥¶¯£¬Æø·ÕÊ®·ÖÈÈÁÒ¡£×îºóÀ´×Ô¸´µ©´óѧ¡¢ÉϺ£ÖÐÒ½Ò©´óѧ¡¢ÉϺ£Ò©ÎïËù¡¢ÖÆÒ©ÆóÒµµÄ¶àÃûר¼ÒѧÕß½øÐкÏÓ°ÁôÄî¡£ |
» ²ÂÄãϲ»¶
331Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
081200-11408-276ѧ˶Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
274Çóµ÷¼ÁÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
277¡¢Ñ§Ë¶£¬Çóµ÷¼Á ÊýÒ»104£¬
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸Ö£ÖÝ´óѧ²ÄÁÏÓ뻯¹¤085600£¬Çóµ÷¼Á
ÒѾÓÐ33È˻ظ´
0854µç×ÓÐÅÏ¢319Çóµ÷¼Á£¨½ÓÊÜ¿çרҵµ÷¼Á£©
ÒѾÓÐ5È˻ظ´
388µ÷¼Á
ÒѾÓÐ3È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
388Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´














»Ø¸´´ËÂ¥